Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.

Tommaso GuerraFrancesca CaputoBianca OrlandoDamiano PaolicelliMaria TrojanoPietro Iaffaldano

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)

Although both medications were effective in patients non-responding to first-line agents, natalizumab seems to be superior to fingolimod in RRMS in obtaining NEDA-3 status at 4 years.

Keyphrases

multiple sclerosis
disease activity
rheumatoid arthritis
white matter
systemic lupus erythematosus
end stage renal disease
rheumatoid arthritis patients
newly diagnosed
ankylosing spondylitis
prognostic factors
peritoneal dialysis
juvenile idiopathic arthritis
patient reported outcomes
patient reported